The head of AstraZeneca’s US operations believes that legislative plans to allow the US government to negotiate drug prices with the industry are far from being a done deal, despite the determination of Democratic political leaders to make it happen.
Pharma Still Hoping To Block US Medicare Price-Setting Legislation
While Democratic politicians – and most voters – want to see drug pricing negotiations introduced in the US for the first time, pharma leaders still believe a deal on out of pocket costs will be agreed instead.
More from Pricing Debate
• By
Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.
• By
Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.
• By
Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.
• By
Respondents to a Senate investigation that could re-energize 340B reform efforts said hospitals offer patient assistance programs and use 340B revenue for “capital improvement projects” and “community benefit programs,” though they do not account for specific program revenue allocations.
More from Market Access
• By
Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.
• By
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.
• By
Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.